唑来膦酸联合降钙素治疗高龄骨质疏松性骨折疗效及对骨密度、骨代谢的影响被引量：4

下载PDF

导出

摘要目的:探讨唑来膦酸联合降钙素治疗高龄骨质疏松性骨折疗效及骨密度、骨代谢影响。方法:选取2015年4月至2017年2月医院收治的高龄骨质疏松性骨折患者106例,随机将其分为对照组和研究组,各53例。两组入院后均采用闭合复位髓内钉固定术治疗,对照组在术后予以降钙素辅助治疗,而研究组在术后予以唑来膦酸联合降钙素辅助治疗,两组均持续治疗12个月。比较两组患者治疗前后骨密度、骨代谢标志物、视觉模拟评分法评分(VAS)以及髋关节功能评分(Harris)的变化情况。结果:治疗后,研究组骨代谢标志物PCT、CTX均显著低于对照组,而PINP、BGP则高于对照组(P<0.01);研究组腰椎及左侧股骨颈骨密度均显著高于对照组(P<0.01);研究组VAS评分显著低于对照组,而Harris评分则高于对照组(P<0.01)。结论:唑来膦酸联合降钙素辅助可有效减轻高龄骨质疏松性骨折患者疼痛,改善其机体骨密度以及骨代谢,促进骨愈合,疗效显著,值得临床推荐。

作者李端午罗晶刘轶

机构地区永丰县中医院骨科

出处《长江大学学报（自然科学版）》 CAS 2018年第20期26-28,共3页 Journal of Yangtze University(Natural Science Edition)

关键词唑来膦酸降钙素高龄骨质疏松性骨折

分类号 R274 [医药卫生—中医骨伤科学]

引文网络
相关文献

参考文献6

1陈立,李佳,韩海滨,彭彦嫣,毛美华.唑来膦酸对绝经后骨质疏松患者骨密度、骨代谢指标、生活质量及疗效的影响[J].河北医药,2016,38(12):1789-1791. 被引量：16
2宋碧晖.唑来膦酸与降钙素对老年骨质疏松性股骨转子间骨折疗效的影响对比观察[J].创伤外科杂志,2017,19(3):207-210. 被引量：13
3邹菁,黄东永,黄远源,陈敏,黄仕光,王友洛.唑来膦酸联合降钙素对老年骨质疏松性骨折患者骨密度和VAS评分的影响[J].河北医药,2016,38(4):526-528. 被引量：22
4黎立,司裕.强骨胶囊联合鲑鱼降钙素针剂治疗对老年骨质疏松性压缩骨折患者骨密度及骨代谢的影响[J].海南医学院学报,2016,22(16):1809-1811. 被引量：26
5李莎莎,唐海英,孙海燕,高林林.唑来膦酸联合鲑降钙素对绝经后骨质疏松性骨折的影响[J].中国现代应用药学,2015,32(3):355-358. 被引量：8
6陈锐雄,王晓锋,张志文,邬哲慧,丘龙海.唑来膦酸治疗高龄骨质疏松性不稳定转子间骨折临床效果观察[J].创伤外科杂志,2017,19(1):45-48. 被引量：9

二级参考文献65

1中华人民共和国卫生部.中药新药治疗骨质疏松症的临床研究指导原则(试行).北京:中国医药科技出版社,2002:356-360.
2HUANG S, L1N H, ZHU X, et al. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis [J]. Endokrynol Pol, 2014, 65(2): 96-104.
3XIE H, TAn L F, HE X B. Efficacy of sodium zoledronic joint salmon calcitonin treatment of elderly patients with primary osteoporosis [J].山西医药杂志, 2011, 40(10): 1027-1028.
4ZHENG G X, ZHAO X O, LIU G L, et al. Oswestry disability index assess the credibility of low back pain patients [J]. 中国脊柱脊杂志, 2002, 12(1): 13-15.
5KHAJURIA D K, RAZDAN R, MAHAPATRA D R. Drugs for the management of osteoporosis: a review [J]. Rev Bras Reumatol, 2011, 51(4): 365-371,379-382.
6DIRSCHL D R, HENDERSON R C, OAKLEY W C. Accelerated bone mineral loss following a hip fi'acture: a prospective longitudinal study [J]. Bone, 1997, 21(1): 79-82.
7MURAD M H, DRAKE M T, MULLAN R J, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis [J]. J Clin Endocrinol Metab, 2012, 97(6): 1871-1880.
8KHAJURIA D K, RAZDAN R, MAHAPATRA D R. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarcbitecture and mechanical properties in osteopenic ovariectomized rats [J]. J Orthop Sci, 2014, 19(4): 646-56.
9COSMAN F, KEAVENY T M, KOPPERDAHL D, Et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene [J]. J Bone Miner Res, 2013, 28(6): 1328-1336.
10MUSCHITZ C, KOCIJAN R, FAHRLEITNER-PAMMER A, et al. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density [J]. J Bone Miner Res, 2013, 28(1): 196-205.